Queen City Angels
05/26/2026 | Press release | Archived content
Need for a tolerable and efficacious…
At the recent European Society for Pediatric Dermatology meeting, a peer-reviewed poster was presented on the clinical need and market opportunity for an effective and well-tolerated molluscum contagiosum (MC) treatment. The poster highlighted Alphyn Biologics Zabalafin Hydrogel as a drug that could potentially fill that need. Precefi, our partner in managing the Phase 2 trial of MC, presented the poster after extensive research on the market.
We look forward to sharing results of Alphyn Biologics Phase 2 trial of MC later this year.
Read More Details >
We look forward to sharing results of Alphyn Biologics Phase 2 trial of MC later this year.
Read More Details >
Queen City Angels published this content on May 26, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on September 25, 2026 at 05:01 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]